Dengue vaccine is only recommended in those who have previously had dengue fever. It is given as three injections over a year.
Statistics:
The global dengue vaccine market is estimated to account for US$ 1,262.0 Mn in terms of value by the end of 2027.
Global Dengue Vaccine Market: Drivers
Increasing demand for dengue vaccine is expected to propel growth of the global dengue vaccine market. For instance, the researchers at International Vaccine Institute, South Korea, projected that around 7.8–62.9 million doses of dengue vaccine are required for only routine vaccination of 12–23 mo cohort in first 5 years of the period 2015–2022 with different vaccination schedules.
Global Dengue Vaccine Market: Opportunities
R&D of vaccines that are effective against all age groups is expected to offer lucrative growth opportunities for players in the global dengue vaccine market. For instance, in November 2019, Takeda Pharmaceutical Company Limited announced that TAK-003, its dengue vaccine candidate demonstrated protection in children ages four to 16 years, regardless of previous dengue exposure.
Global Dengue Vaccine Market: Restraints
Dengue vaccines such as Dengvaxia poses high risk to people without prior dengue infection. This is expected to hinder adoption of dengue vaccines, thereby hindering growth of the market.
Key Takeaways:
The Government Institutes segment in the global dengue vaccines market was valued at US$ 169.6 Mn in 2019 and is expected to reach US$ 657.6 by 2027 at a CAGR of 18.5% during the forecast period. The growth of the segment is attributed increase in government initiatives to promote awareness and provide vaccination facility to cope up with increasing incidence of dengue in respective countries.
Market Trends
Major players in the market are focused on developing recombinant subunit vaccines that are effective against dengue. For instance, Merck is assessing the immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue. The study completed phase I stage as of 2019.
Major players in the market are focused on adopting M&A strategies to expand their product portfolio. For instance, in January 2019, Takeda Pharmaceutical Company Limited completed acquisition of Shire plc.
Global Dengue Vaccine Market: Competitive Landscape
Major players operating in the global dengue vaccine market include, Sanofi, Takeda Pharmaceutical Company Limited, GlaxoSmithKline, and Merck & Co.
Global Dengue Vaccine Market: Key Developments
- January 2020: Codagenix, a company developing vaccines and viral therapies for illnesses ranging from the flu and respiratory viruses to dengue fever, raised US$ 20 million in a new round of financing
- November 2019: Takeda Pharmaceutical Company Limited started a plant to produce dengue vaccine in Germany
Segmentation
- Dengue Vaccine Market, By End User:
- Hospitals
- Government Institutes
- NGOs
- Dengue Vaccine Market, By Region:
- Latin America
- By End User
- Hospitals
- Government Institutes
- NGOs
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Asia Pacific
- By End User
- Hospitals
- Government Institutes
- NGOs
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By End User
- Hospitals
- Government Institutes
- NGOs
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By End User
- Hospitals
- Government Institutes
- NGOs
- By Country:
- South Africa
- Central Africa
- North Africa
- Rest of World
- By End User
- Hospitals
- Government Institutes
- NGOs
- Company Profiles
- Sanofi *
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Takeda Pharmaceutical Company Limited
- GlaxoSmithKline
- Merck & Co.
“*” marked represents similar segmentation in other categories in the respective section.
